多基因架构揭示药物性肝损伤的潜在易感性
研究基于既往大规模全基因组关联研究汇总的众多基因组位点效应,构建了药物性肝损伤(DILI)的多基因风险评分(PRS)。该PRS在法昔洛韦、阿莫西林-克拉维酸或氟氯西林治疗患者及多种药物处理的原代肝细胞和干细胞衍生类器官中预测DILI易感性。通路分析提示未折叠蛋白反应和氧化应激等过程,计算机筛选识别出可引发高PRS个体肝细胞转录组特征的化合物,支持「培养皿中的多基因性」策略用于新药安全筛选和临床试验设计。
要点
- PRS可预测多种药物在患者及肝细胞/类器官模型中的DILI易感性。
- 通路分析揭示未折叠蛋白反应和氧化应激与DILI易感性相关。
- 「培养皿中的多基因性」策略有望用于新药安全筛选和临床试验设计。
核心结论
- DILI易感性具有多基因架构,PRS可在肝细胞水平预测药物易感性。
研究设计与样本
- 基于既往大规模全基因组关联研究汇总的基因组位点效应构建DILI多基因风险评分。
- 在法昔洛韦、阿莫西林-克拉维酸或氟氯西林治疗患者中评估PRS预测DILI易感性。
- 在多种供体的原代肝细胞和干细胞衍生类器官中,用超过十种不同药物处理评估PRS预测易感性。
主要发现
- PRS预测了法昔洛韦、阿莫西林-克拉维酸或氟氯西林治疗患者的DILI易感性。
- PRS预测了多种供体原代肝细胞和干细胞衍生类器官对超过十种不同药物的DILI易感性。
- 通路分析突出未折叠蛋白反应和氧化应激等既往与DILI相关的过程。
- 计算机筛选识别出可引发高PRS个体肝细胞转录组特征的化合物,支持机制联系并提示新药安全筛选方法。
临床怎么用
- PRS可能用于识别DILI高风险患者,指导临床用药监测。
- 「培养皿中的多基因性」策略或可辅助新药候选物的安全筛选。
- 研究提示可基于PRS设计更安全、更高效和稳健的临床试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Drug-induced liver injury (DILI) is a leading cause of termination in drug development programs and removal of drugs from the market; this is partially due to the inability to identify patients who are at risk1. In this study, we developed a polygenic risk score (PRS) for DILI by aggregating effects of numerous genome-wide loci identified from previous large-scale genome-wide association studies2. The PRS predicted the susceptibility to DILI in patients treated with fasiglifam, amoxicillin-clavulanate or flucloxacillin and in primary hepatocytes and stem cell-derived organoids from multiple donors treated with over ten different drugs. Pathway analysis highlighted processes previously implicated in DILI, including unfolded protein responses and oxidative stress. In silico screening identified compounds that elicit transcriptomic signatures present in hepatocytes from individuals with elevated PRS, supporting mechanistic links and suggesting a novel screen for safety of new drug candidates. This genetic-, cellular-, organoid- and human-scale evidence underscored the polygenic architecture underlying DILI vulnerability at the level of hepatocytes, thus facilitating future mechanistic studies. Moreover, the proposed 'polygenicity-in-a-dish' strategy might potentially inform designs of safer, more efficient and robust clinical trials.
引用
- Koido M, Kawakami E, Fukumura J, et al. Polygenic architecture informs potential vulnerability to drug-induced liver injury. Nat Med. 2020. PMID: 32895570. doi:10.1038/s41591-020-1023-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。